These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12893358)

  • 41. Patterns of recurrence after low-dose-rate prostate brachytherapy: a population-based study of 2223 consecutive low- and intermediate-risk patients.
    Lo AC; Morris WJ; Pickles T; Keyes M; McKenzie M; Tyldesley S
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):745-51. PubMed ID: 25752387
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of secondary hormonal therapy in the management of recurrent prostate cancer.
    Ryan CJ; Small EJ
    Urology; 2003 Dec; 62 Suppl 1():87-94. PubMed ID: 14747046
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of a symptomatic intracranial meningioma in a male-to-female transsexual after initiation of hormone therapy.
    Deipolyi AR; Han SJ; Parsa AT
    J Clin Neurosci; 2010 Oct; 17(10):1324-6. PubMed ID: 20594855
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analysis the causes of radiosurgical failure in intracranial meningiomas treated with radiosurgery.
    Kim M; Cho YH; Kim JH; Kim CJ; Kwon DH
    Clin Neurol Neurosurg; 2017 Mar; 154():51-58. PubMed ID: 28129632
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Neoadjuvant hormone therapy before prostatectomy for cancer localized to the prostate].
    Boccon-Gibod L
    Prog Urol; 1997 Feb; 7(1):97-8. PubMed ID: 9116748
    [No Abstract]   [Full Text] [Related]  

  • 46. Progression-Free Survival and Factors Associated with Postoperative Recurrence in 126 Patients with Atypical Intracranial Meningioma.
    Phonwijit L; Khawprapa C; Sitthinamsuwan B
    World Neurosurg; 2017 Nov; 107():698-705. PubMed ID: 28838877
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
    Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
    Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
    Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Bone metastatic evolution of a recurrent meningioma: case report].
    Tournat H; Huchet A; Ouhabrache N; Thomas IC; Roubaud G; Maire JP
    Cancer Radiother; 2006 Dec; 10(8):590-4. PubMed ID: 16876455
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of particle radiotherapy for the re-irradiation of recurrent intracranial meningioma.
    El Shafie RA; Czech M; Kessel KA; Habermehl D; Weber D; Rieken S; Bougatf N; Jäkel O; Debus J; Combs SE
    Radiat Oncol; 2018 May; 13(1):86. PubMed ID: 29739417
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Study of intermittent endocrine therapy in patients presenting with biologic recurrence after radical prostatectomy or radiotherapy].
    de la Taille A; Zerbib M; Conquy S; Amsellem-Ouazana D; Saighi D; Debré B
    Prog Urol; 2002 Apr; 12(2):240-7. PubMed ID: 12108338
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Keyrole of endocrinology in the victory against prostate cancer].
    Labrie F
    Bull Cancer; 2006 Sep; 93(9):949-58. PubMed ID: 16980238
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Spot scanning-based proton therapy for intracranial meningioma: long-term results from the Paul Scherrer Institute.
    Weber DC; Schneider R; Goitein G; Koch T; Ares C; Geismar JH; Schertler A; Bolsi A; Hug EB
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):865-71. PubMed ID: 22138457
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Editorial: radiosurgery and atypical meningiomas.
    Elder JB; Chiocca EA
    J Neurosurg; 2012 Oct; 117(4):676-8. PubMed ID: 22920959
    [No Abstract]   [Full Text] [Related]  

  • 55. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.
    Matsushima H; Goto T; Hosaka Y; Kitamura T; Kawabe K
    Cancer; 1999 Apr; 85(8):1822-7. PubMed ID: 10223578
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Postmenopausal hormone replacement therapy and meningioma.
    Prescrire Int; 2010 Jun; 19(107):120. PubMed ID: 20738039
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recurrence of cranial base meningiomas.
    Mathiesen T; Lindquist C; Kihlström L; Karlsson B
    Neurosurgery; 1996 Jul; 39(1):2-7; discussion 8-9. PubMed ID: 8805134
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hormonal therapy for fertility and huge meningioma: a purely random association?
    Frassanito P; De Bonis P; Mattogno PP; Novello M; Anile C
    Acta Neurol Belg; 2012 Sep; 112(3):299-301. PubMed ID: 22426675
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
    Van Poppel H; Klotz L
    Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Triptorelin embonate: a 6-month formulation for prostate cancer.
    Whelan P
    Expert Opin Pharmacother; 2010 Dec; 11(17):2929-32. PubMed ID: 20969451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.